Empowering gene therapy development with Countagen’s disruptive gene editing validation technology

Important results from the project

This grant has given us the opportunity to bring in Civitta to help us write our proposal. The project has consisted of workshops, analysis, writing and creation of visual material. We have achieved the goal of submitting Step 1-proposal, but unfortunately have not yet submitted Step 2-proposal. The project has led to a better general description of the company, a sharper description of our business model and our future products, which we can use for various types of external communication.

Expected long term effects

The project is expected to enable Countagen to fully develop and commercialize its gene editing validation platform, accelerating safe and precise gene therapies. Long-term effects include improved access to innovative treatments, reduced validation costs, strengthened European biotech competitiveness, enhanced regulatory readiness, and creation of high-skilled jobs. The technology also supports rare disease therapies and contributes to precision medicine globally.

Approach and implementation

Since we were not invited to Step 2, we needed to extend WP 1 and improve all identified weaknesses of the Step 1- proposal. After the resubmission results were published, we strengthened the Step 1 proposal further and submitted it a 3rd time. Hence, we could not conclude WP2. WP3 on the business plan and commercialisation strategy was only partially completed. We could not begin WP4. We intend to complete all tasks described in the planning project in the next five months.